Drilldown: Medicines
Use the filters below to narrow your results.
generic:
brand:
classes:
Anti-amyloid beta (Aβ) monoclonal antibody (2) ·
targets pyroglutamated Aβ in plaques (1) ·
[[:Category:B-vitamins|B-vitamin]] (2) ·
[[:Category:Hematinics|Hematinic]] (2) ·
[[:Category:Hormonal_contraceptives|Hormonal contraceptive (Depo)]] (1) ·
[[:Category:NMDA antagonists|NMDA receptor antagonist]] (1) ·
[[:Category:Opioid analgesics|Opioid analgesic (full mu-agonist)]] (1) ·
[[:Category:Progestogens|Progestin (synthetic progestogen)]] (1) ·
[[:Category:Schedule II controlled substances|Schedule II controlled substance]] (1) ·
[[:Category:Sex_hormones|Sex hormone]] (1) ·
[[:Category:Vitamins|Vitamin]] (2)
mechanism:
uses:
Alzheimer disease (FDA accelerated approval June 2021; '''withdrawn from market January 2024''' by manufacturer Biogen). At time of approval indicated for MCI or mild dementia stage of AD. (1) ·
Alzheimer disease (MCI or mild dementia stage), FDA-approved July 2024 (1) ·
'"`UNIQ--vote-0000004C-QINU`"', '"`UNIQ--vote-0000004D-QINU`"', '"`UNIQ--vote-0000004E-QINU`"' (1) ·
'"`UNIQ--vote-000005B3-QINU`"', '"`UNIQ--vote-000005B4-QINU`"', '"`UNIQ--vote-000005B5-QINU`"', '"`UNIQ--vote-000005B6-QINU`"' (1) ·
'"`UNIQ--vote-00000607-QINU`"', '"`UNIQ--vote-00000608-QINU`"', '"`UNIQ--vote-00000609-QINU`"', '"`UNIQ--vote-0000060A-QINU`"' (1) ·
'"`UNIQ--vote-00000F1B-QINU`"', '"`UNIQ--vote-00000F1C-QINU`"', '"`UNIQ--vote-00000F1D-QINU`"', '"`UNIQ--vote-00000F1E-QINU`"', '"`UNIQ--vote-00000F1F-QINU`"' (1)
starting dose:
None (1) ·
0.4 mg PO daily (general prevention); 0.8-1 mg/d in pregnancy; 4 mg/d for women with prior NTD-affected pregnancy; 1 mg/d during methotrexate therapy (1) ·
700 mg IV q4w × 3 doses, then 1400 mg IV q4w; may discontinue when amyloid PET shows clearance (1) ·
Contraception: Depo-Provera 150 mg IM every 13 weeks; Depo-SubQ 104 mg SC every 12-13 weeks; oral cycling: 5-10 mg PO daily ×5-10 days for amenorrhea (1) ·
Replacement: 1000 mcg IM daily for 1 week, then weekly for 4 weeks, then monthly; or 1000-2000 mcg PO daily (effective even in pernicious anemia via passive diffusion); intranasal 500 mcg weekly (1) ·
Was 1 mg/kg IV q4w × 2, then 3 mg/kg × 2, then 6 mg/kg × 2, then 10 mg/kg q4w (1)
preparations:
0.4, 0.8, 1 mg OTC; 1 mg Rx; 5 mg/mL injection (1) ·
100, 250, 500, 1000, 5000 mcg tablets (OTC and Rx); 1000 mcg/mL injection; intranasal spray; sublingual (1) ·
2.5, 5, 10 mg oral tablets; Depo-Provera 150 mg/mL IM; Depo-SubQ Provera 104 mg/0.65 mL (1) ·
350 mg/20 mL vial for IV infusion (1) ·
Tablets 5, 10, 40 mg (40 mg dispersible restricted to OTPs); oral concentrate 10 mg/mL; oral solution 1, 2, 10 mg/mL; injection 10 mg/mL (1) ·
Was: 170 mg/1.7 mL, 300 mg/3 mL vials for IV infusion (1)
fda max:
1 mg/d typical Rx; higher in specific indications (1) ·
1400 mg q4w (1) ·
Indication-specific (1) ·
No formal hard ceiling; in MOUD maintenance, doses typically remain at or below 120 mg/day with higher doses reserved for documented under-treatment after careful clinical assessment (1) ·
No strict ceiling; water-soluble vitamin, low toxicity (1) ·
Withdrawn 2024 (1)
routes: (Click arrow to add another value)
onset:
Amyloid PET clearance within months; cognitive benefit over 18 months (1) ·
Contraceptive within 24 hours if given in first 5 days of cycle; otherwise backup for 7 days (1) ·
Hematologic response within days (1) ·
Oral analgesic effect 30-60 minutes; opioid-withdrawal suppression 30 minutes (oral); IV ~10 minutes (1) ·
PET Aβ reduction over months (1) ·
Reticulocyte response at 3-5 days; neurologic recovery weeks to months (and may be incomplete if longstanding) (1)
duration:
Analgesic effect 4-8 hours (much shorter than half-life would suggest, due to receptor kinetics); MOUD effect (opioid withdrawal suppression) 24-36 hours per single daily dose (1) ·
Depot IM 13 weeks (designed); often persists longer (1) ·
N/A (replacement) (2) ·
Treatment can be discontinued upon achieving amyloid clearance (1) ·
Withdrawn (1)
halflife:
bioavailability:
pregnancy:
None (1) ·
Contraindicated in known pregnancy.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Discontinued/withdrawn (1) ·
Limited data (1) ·
Routinely supplemented in pregnancy and preconception to prevent neural tube defects.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Routinely supplemented in vegan pregnancies and pernicious anemia.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1)
legal:
None (1) ·
OTC (low-dose) and [[USLegal:Prescription only|Rx-only]] (1 mg, injectable) in US (1) ·
OTC (low/mid-dose oral) and [[USLegal:Prescription only|Rx-only]] (injection, intranasal) in US (1) ·
Rx; ARIA monitoring required (1) ·
Withdrawn from US market January 2024 (1) ·
[[USLegal:Prescription only|Rx-only]] in US. Carries a '''Boxed Warning''' for bone mineral density loss with prolonged use (≥2 years; partially reversible after discontinuation)'"`UNIQ--ref-00000F22-QINU`"' (1)
Showing below up to 6 results in range #1 to #6.